DCM
CATX icon

DAFNA Capital Management’s Perspective Therapeutics CATX Stock Holding History

DAFNA Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,000
Closed -$138K – 86
2025
Q4 		$138K Buy
+50,000
New +$143K 0.03% 77
2025
Q1 		– Sell
-130,169
Closed -$415K – 85
2024
Q4 		$415K Sell
130,169
-100,153
-43% -$818K 0.11% 76
2024
Q3 		$3.07M Sell
230,322
-1,312
-0.6% -$17.4K 0.73% 33
2024
Q2 		$2.31M Sell
231,634
-78,730
-25% -$1.14M 0.55% 40
2024
Q1 		$3.69M Buy
+310,364
New +$2.65M 0.84% 32

Other funds holding CATX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DAFNA Capital Management's CATX Position: Q1 2026 in Review

DAFNA Capital Management sold out of Perspective Therapeutics (CATX) in Q1 2026, closing a stake of 50,000 shares — an estimated $138K sold.

DAFNA Capital Management first reported a position in CATX in Q1 2024 and held it in 5 quarters. The position peaked at $3.69M in Q1 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • DAFNA Capital Management reported no remaining Perspective Therapeutics position as of Q1 2026 after selling out during the quarter.
  • DAFNA Capital Management sold 50,000 Perspective Therapeutics shares in Q1 2026, an estimated $138K.
  • DAFNA Capital Management first reported a position in Perspective Therapeutics in Q1 2024 and held it in 5 quarters.
  • DAFNA Capital Management's Perspective Therapeutics position peaked at $3.69M in Q1 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.